Ironwood(US:IRWD)2023-02-16 15:09Financial Performance & Guidance - Ironwood's total revenues reached $1.002 billion in FY 2022[26] - GAAP net income for FY 2022 was $175.065 million, or $1.13 per share basic and $0.96 per share diluted[26,30] - Adjusted EBITDA for FY 2022 was $251.755 million[30] - Ironwood anticipates LINZESS U S net sales growth of 3%-5% in FY 2023[27] - Ironwood projects revenues between $420 million and $435 million and adjusted EBITDA exceeding $250 million for FY 2023[27] LINZESS Performance - LINZESS U S net sales reached $1.002 billion in FY 2022[26,31] - LINZESS commercial margin was 73% in FY 2022[26,31] - LINZESS prescription demand experienced a 9% year-over-year growth[7] - LINZESS achieved a market-leading TRx share of 45%[7] Pipeline Development - An sNDA for functional constipation (FC) in pediatric patients ages 6-17 has been submitted, with priority review granted and a PDUFA date of June 14, 2023[7,16] - Proof of concept study dosing for IW-3300 in patients with IC/BPS is expected to begin in early 2023[7] - Early data from the CNP-104 proof of concept study in primary biliary cholangitis (PBC) is expected in the second half of 2023[16]